1. Home
  2. CIGL vs IFRX Comparison

CIGL vs IFRX Comparison

Compare CIGL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CIGL

Concorde International Group Ltd Class A Ordinary Shares

HOLD

Current Price

$1.72

Market Cap

59.4M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.20

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIGL
IFRX
Founded
1997
2007
Country
Singapore
Germany
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.4M
71.1M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
CIGL
IFRX
Price
$1.72
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
20.9K
658.1K
Earning Date
09-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,072,733.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
6.32
N/A
52 Week Low
$1.40
$0.71
52 Week High
$31.06
$2.77

Technical Indicators

Market Signals
Indicator
CIGL
IFRX
Relative Strength Index (RSI) 46.92 57.33
Support Level $1.55 $0.99
Resistance Level $1.94 $1.16
Average True Range (ATR) 0.16 0.08
MACD 0.01 0.02
Stochastic Oscillator 56.10 89.13

Price Performance

Historical Comparison
CIGL
IFRX

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: